Combining these therapies is not only biologically compelling for their anti-tumor efficacy but also to reduce the toxicity of each monotherapy, making the anti-CD137/anti-CTLA-4 combination the top choice for clinical translation. The gene discussed is TNFRSF9; the disease is neoplasm.